Several preclinical studies have indicated the importance of the IGF axis for PCa progression and provided the basis for clinical trials with the IGF-1R as an anti-cancer target, alone or in combination with conventional therapies (recently reviewed in [23]). The gene discussed is IGF1R; the disease is posterior cortical atrophy.